# A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

> **NCT05508867** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 203 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** favezelimab/pembrolizumab
- **DRUG:** bendamustine
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT05508867
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2025-09-03
- **Final completion:** 2026-01-08
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05508867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05508867, "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05508867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*